about
Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analoguesFixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products.A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprostDiurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension.Enhanced eyelashes: prescription and over-the-counter options.Management of hypotrichosis of the eyelashes: Focus on bimatoprostProstamides (prostaglandin-ethanolamides) and their pharmacology.Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells.Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials.Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol.In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytesBimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical TrialsPeriocular discoloration after using a prostaglandin analog for eyelash enhancement: evaluation with reflectance confocal microscopy.An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial.Bilateral serous detachment associated with latanoprost/timolol fixed combination use: a report of one phakic case.Change in prostaglandin expression levels and synthesizing activities in dry eye disease.Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study.Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patientsBimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trialAntiglaucoma drugs: The role of preservative-free formulations.Influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucoma.Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trialsTravoprost in the management of open-angle glaucoma and ocular hypertensionPharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides.Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patientsBimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature.Tafluprost for glaucoma.A review of the use of latanoprost for glaucoma since its launch.Topical bimatoprost 0.03% and iatrogenic eyelid and orbital lipodystrophy.Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease.Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma.Effectiveness of the ICare rebound tonometer in patients with overestimated intraocular pressure due to tight orbit syndrome.Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.Travoprost and latanoprost, but not bimatoprost, induced nausea, vomiting and diarrhoea.Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis.Intraocular Pressure and Conjunctival Hyperaemia with Bimatoprost Every 48 Hours Versus Every 24 Hours.Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.
P2860
Q28301055-E9212D93-A43A-4B36-9898-548AA94C254CQ30588260-D1E43522-24C9-40F3-9C07-92889D2900CBQ34399842-087DBC8A-51BD-4839-95C6-D21B9A4A467EQ34439352-E8E99428-16CE-45EC-BD14-3438214D7BD5Q34565148-0FE5C147-8797-4600-97BB-E2B6A1FA6EDCQ34620347-8FD9B7FC-E880-4C58-87E3-1E2444C81EAEQ34667670-20752E0A-B985-4604-87C9-16713B29D979Q34730252-1F7AB1D3-5F73-45FA-B421-C59E3F3D8F12Q35050234-D714E336-7141-4CB7-B330-0B98D0D8A8C4Q35617544-217FEF1E-E78E-46CE-8DBE-FCF2479CDC10Q35860207-958F7E82-C8C5-4912-A41B-CF8FAAD96ACFQ35871898-869092F4-8C5B-4F55-8CBC-CFEE5828AFABQ36123302-41B0DA88-1EE1-430C-9C52-B7A3CA4EBF4BQ36487013-94FC1B11-AC5E-43F2-B925-390D31E7B3A8Q36495854-F24B9706-CA96-4189-BC16-9EE3C25DCBBAQ36945904-E0CCF0C9-97B3-4BCB-B998-47808383E0A9Q36985297-84E6336A-2DA0-412F-B4EA-6B43FEC3860AQ37027652-C25B7F9D-0D81-4057-A130-2D9BF2D09A45Q37030839-E9538328-1DC6-4207-B34D-7C42B1B81B06Q37060734-FBD41D19-DF79-45F3-B2A8-2D272DF313C8Q37067698-D6EDBFB6-1CD4-46D5-8422-10859B997F0AQ37091331-A6B368A6-3922-4B6E-AFB3-11044E02CEA7Q37236653-F5D2D018-8E5A-4806-BDD9-E95ECD26C3ABQ37636153-1EF455F3-5ED1-4F19-8E7A-952911C38DF1Q37697869-0427983E-0D2F-41F6-AC0F-83BC24C9748EQ37729889-E6AFB628-ED95-4DC8-A852-574B16B2A0F6Q37776497-CD7BF02E-4E5F-4E15-A26D-422A87E16464Q37931967-37A1CEA1-89F1-44E0-9837-44FFEEF234B8Q37986149-A60788AA-86B1-428B-B48C-E73035AD504EQ38040040-CB4C9959-B3D2-4233-AF05-BB8EE55DA658Q38063963-37750B25-3EC5-49C0-97DA-791D732C5EC9Q38339962-6773F31B-0552-4BC2-97C5-098DC6FA850FQ38434738-75800E99-1B1D-4A67-86B2-59B2646D8EDAQ38819721-E1885C2E-2B48-4ED1-8B23-B1723410C899Q39448716-71B9BB05-F570-4660-8F61-2FC363A5A57DQ41717117-DF016D6A-F817-431A-A228-292B8F29CB3EQ42181281-E4F1CD66-0C77-4F5D-AE56-C376F2A21444Q42183554-BFB36732-B988-4DF8-8612-B1D26217F32DQ45764566-9D08283F-84B7-479B-90AA-B320FF3A95ABQ47381165-89C1A73B-01CA-4A4A-832C-893CB304E8F9
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The side effects of the prostaglandin analogues.
@ast
The side effects of the prostaglandin analogues.
@en
type
label
The side effects of the prostaglandin analogues.
@ast
The side effects of the prostaglandin analogues.
@en
prefLabel
The side effects of the prostaglandin analogues.
@ast
The side effects of the prostaglandin analogues.
@en
P2860
P356
P1476
The side effects of the prostaglandin analogues.
@en
P2093
Gábor Holló
P2860
P356
10.1517/14740338.6.1.45
P407
P577
2007-01-01T00:00:00Z